Efficacy, safety and tolerability of mometasone fuorate 0.1% ointment in chronic eczema

Authors

  • Zahida Rani
  • Atif Hasnain Kazmi
  • Riaz A Sheikh
  • Azer Rashid
  • Javaid Waseem
  • Ali Raza

Keywords:

Eczema, mometasone furoate, itching

Abstract

Introduction Eczema covers a wide range of skin problems, which trouble people at different stages of their lives. Mometasone furoate has been reported to be an effective vasoconstrictive agent on human skin. Objective To evaluate the therapeutic efficacy, safety and tolerability of mometasone furoate ointment 0.1% in chronic eczema following a four-week course of therapy and to record the main events in the cascade of eczema. Patients and methods This quasi-experimental, multi-center study was conducted in four cities of Pakistan (Karachi, Lahore, Islamabad, and Peshawar) from December, 2005 to February, 2006. A total 180 patients aged ≥ 24 months of either sex with chronic eczema without secondary infection were recruited while pregnancy, known hypersensitivity to corticosteroids, presence of skin atrophy, those on systemic steroids within 28 days were excluded. Patients were instructed to apply a thin layer of ointment once daily. Tubes of mometasone furoate ointment were dispensed to the patients on days 1, 8 and 15 of the study. Patients were asked to return the used tubes at the next weekly follow-up visit. SPSS-13.0 was used for statistical analysis. Friedman test was applied to compare the significance of clinical outcome, relief in signs/symptoms and patient’s comfort at p<0.05. Results On first follow up 8 days after treatment, significant majority (77%) showed improvement and in 7 (4%) patients fully resolved. After 15 days, 75% showed improvement and resolved in 19% patients. After 21 days of treatment, improvement was seen in 32% and 55% had resolved. Efficacy in terms of relief in signs and symptoms on last follow up >21 days after treatment revealed significant resolution of signs and symptoms (p<0.001). The cumulative level of comfort on various follow up visits was found significant (p<0.001). Conclusion Mometasone furoate ointment is significantly effective in relief in sign and symptoms and provides a high level of comfort after the treatment of chronic eczema. 

References

Medansky RS, Bressinck R, Cole GW, et al. Mometasone furoate ointment and cream 0.1% in treatment of psoriasis: comparison with ointment and cream formulation of fluocinolone acetonide 0.025% and triamcinolone acetonide 0.1%. Cutis 1988; 42: 480-6.

Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol 2002; 3: 47-58.

Faergemann J, Christensen O, Sjovall P et al. An open study of efficacy and safety of long-term treatment with Mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2000 ; 14 : 393-6.

Veien NK, Olholm Larsen P, Thestrup-Pedersen K, Schou G. Long-term, intermittent treatment of chronic hand eczema with Mometasone furoate. Br J Dermatol 1999; 140: 882-6.

Bressinck R, Williams J, Peets E. Comparison of the effects of mometasone furoate ointment 0.1% and hydrocortisone ointment 1% on adrenocortical function in psoriasis patients. Today’s Therapeutic Trends 1988; 5: 25-35.

Green C, Colquitt JL, Kirby J et al. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation. Health Technol Assess 2004; 8: 1-120.

Downloads

Published

2016-12-28

How to Cite

1.
Rani Z, Kazmi AH, Sheikh RA, Rashid A, Waseem J, Raza A. Efficacy, safety and tolerability of mometasone fuorate 0.1% ointment in chronic eczema. J Pak Assoc Dermatol [Internet]. 2016Dec.28 [cited 2025Apr.27];17(1):21-7. Available from: https://jpad.com.pk/index.php/jpad/article/view/680

Issue

Section

Original Articles

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>